Table:
Exclusion criteria for both HEPATICUS-1 and HEPATICUS-2
Patients, whose mortality approaches 100%, or who are not likely to benefit from treatment(intervention with ADVOS is likely to be futile)
Patients, whose current medical condition does not allow treatment with any extracorporeal procedure
Potential conflict with good clinical practice (GCP) or with the declaration of Helsinki
PaO2/FiO2 ≤ 100 mmHg (respiratory SOFA score of 4)
Patient testament excludes the use of life-prolonging measures
Post-operative patients whose liver failure is related to liver surgery
Participation in another clinical study
Patients diagnosed with Creutzfeldt-Jakob disease
Pregnancy
Weight ≥120 kg
Uncontrolled seizures
Mean arterial pressure ≤50 mmHg despite conventional medical treatment
Active or uncontrolled bleeding
Untreatable extrahepatic cholestasis
Patients with MELD-score of 40
Exclusion criteria specific for HEPATICUS-1	Exclusion criteria specific for HEPATICUS-2
Patients with creatinine >5 mg/dl or urine output <200 ml/day(renal SOFA-score of 4)	Patient with known history of chronic liver disease
Patients who receive a vasopressor support of Dopamine >15 μg/kg/min or epinephrine >0.1 μg/kg/min or norepinephrine >0.1 μg/kg/min (cardiovascular SOFA-score of 4)

Transcribe the photo into Markdown format.

| <COLSPAN=2> Exclusion criteria for both HEPATICUS-1 and HEPATICUS-2 | 
 | --- | --- | 
 | <COLSPAN=2> Patients, whose mortality approaches 100%, or who are not likely to benefit from treatment(intervention with ADVOS is likely to be futile) | 
 | <COLSPAN=2> Patients, whose current medical condition does not allow treatment with any extracorporeal procedure | 
 | <COLSPAN=2> Potential conflict with good clinical practice (GCP) or with the declaration of Helsinki | 
 | <COLSPAN=2> PaO2/FiO2 ≤ 100 mmHg (respiratory SOFA score of 4) | 
 | <COLSPAN=2> Patient testament excludes the use of life-prolonging measures | 
 | <COLSPAN=2> Post-operative patients whose liver failure is related to liver surgery | 
 | <COLSPAN=2> Participation in another clinical study | 
 | <COLSPAN=2> Patients diagnosed with Creutzfeldt-Jakob disease | 
 | <COLSPAN=2> Pregnancy | 
 | <COLSPAN=2> Weight ≥120 kg | 
 | <COLSPAN=2> Uncontrolled seizures | 
 | <COLSPAN=2> Mean arterial pressure ≤50 mmHg despite conventional medical treatment | 
 | <COLSPAN=2> Active or uncontrolled bleeding | 
 | <COLSPAN=2> Untreatable extrahepatic cholestasis | 
 | <COLSPAN=2> Patients with MELD-score of 40 | 
 | Exclusion criteria specific for HEPATICUS-1 | Exclusion criteria specific for HEPATICUS-2 | 
 | Patients with creatinine >5 mg/dl or urine output <200 ml/day(renal SOFA-score of 4) | Patient with known history of chronic liver disease | 
 | Patients who receive a vasopressor support of Dopamine >15 μg/kg/min or epinephrine >0.1 μg/kg/min or norepinephrine >0.1 μg/kg/min (cardiovascular SOFA-score of 4) |  |